Inhibrx Biosciences, Inc.

Company Overview

Business Model: Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel biologic therapeutic candidates. The company leverages its proprietary modular protein engineering platforms and deep understanding of target biology to create therapeutic candidates with attributes and mechanisms believed to be superior to current approaches, applicable to challenging, validated targets with high potential. Its current pipeline is primarily focused on oncology.

Market Position: As a clinical-stage company, Inhibrx Biosciences, Inc. does not yet have approved products on the market. Its market position is defined by its innovative protein engineering technologies, which aim to create differentiated, next-generation therapeutics. The company faces competition from major pharmaceutical and biotechnology companies, academic institutions, and research institutions, many of which possess significantly greater resources.

Recent Strategic Developments:

• Separation and Merger (May 2024): Inhibrx Biosciences, Inc. completed a spin-off from its Former Parent, Inhibrx, Inc. This involved a distribution of 92% of Inhibrx Biosciences, Inc.'s common stock to Former Parent stockholders. Concurrently, the Former Parent merged with Art Acquisition Sub, Inc., a wholly-owned subsidiary of Aventis Inc. (a wholly-owned subsidiary of Sanofi S.A.).
• Asset Allocation: Inhibrx Biosciences, Inc. acquired assets and liabilities related to its ongoing programs, INBRX-106 and ozekibart (INBRX-109), its discovery pipeline, and close-out obligations for its previously terminated program, INBRX-105. The INBRX-101 business was transferred to the Acquirer.
• Shareholder Consideration: Former Parent stockholders received $30.00 per share in cash, one contingent value right per share (for a potential $5.00 cash payment upon a regulatory milestone), and one SEC-registered, publicly listed share of Inhibrx Biosciences, Inc. for every four shares of the Former Parent's common stock held.
• Related Party Agreements: Entered into a Separation and Distribution Agreement, Transition Services Agreement, and other agreements with the Former Parent to govern the ongoing relationship, including allocation of employee benefits, taxes, and certain liabilities.

Geographic Footprint: Inhibrx Biosciences, Inc.'s corporate headquarters and primary operations are located in La Jolla, California. Clinical trials for its therapeutic candidates are conducted in the United States and worldwide.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Inhibrx Biosciences, Inc. is a clinical-stage company and has not generated revenue from product sales. The company incurred significant operating losses in 2023 ($219.2 million) and prior periods. The net income of $1,687.6 million in 2024 was primarily driven by a one-time gain of $2,021.5 million related to the transaction with the Acquirer (Sanofi S.A.), including merger consideration, assumption of debt, and reimbursement of transaction costs.

Investment in Growth:

• R&D Expenditure: $203.7 million (2024)
• Capital Expenditures: $2.6 million (2024)
• Strategic Investments: In 2023, the company received an additional 5% equity interest in Phylaxis BioScience, LLC, valued at $1.6 million, following a milestone achievement. This increased its total equity interest to 15%.

Business Segment Analysis

Inhibrx Biosciences, Inc. operates and manages its business as one operating and reportable segment, focusing on drug discovery and development activities for biologic therapeutic candidates. The company's financial results are reviewed at a consolidated level by its Chief Executive Officer, who serves as the chief operating decision-maker.

ozekibart (INBRX-109)

Financial Performance: Research and development expenses are tracked in aggregate and not allocated by specific program. Overall R&D expense was $203.7 million in 2024, an increase of 6% from $191.6 million in 2023, primarily due to increased personnel-related expenses (including stock option acceleration) and clinical trial expenses, partially offset by decreased contract manufacturing expenses following the divestiture of INBRX-101.

Product Portfolio: Ozekibart (INBRX-109) is a precisely engineered tetravalent therapeutic candidate targeting death-receptor 5 (DR5), a TNFRSF member, designed to induce cancer-specific programmed cell death through efficient receptor clustering. It is engineered with proprietary single domain antibody (sdAb) modifications to reduce recognition by pre-existing anti-drug antibodies and minimize on-target liver toxicity.

Key Growth Drivers:

• Chondrosarcoma:
  • Regulatory Designations: Granted FDA Fast Track designation (January 2021) and Orphan Drug designation (November 2021) in the U.S., and European Commission Orphan designation (August 2022) for the treatment of unresectable or metastatic conventional chondrosarcoma.
  • Phase 1 Data (Interim, as of August 9, 2024): In an expansion cohort of 31 evaluable patients, the observed disease control rate (DCR) was 77.8% (42 out of 54 patients), with 3.7% achieving partial responses (PR) and 74.1% achieving stable disease (SD). 55.0% of patients with stable disease showed decreases in tumor size. Median progression-free survival (PFS) was 7.42 months.
  • Phase 2 Trial: A registration-enabling Phase 2 trial in metastatic conventional chondrosarcoma was initiated in June 2021, aiming to enroll approximately 200 patients globally (2:1 randomization of ozekibart (INBRX-109) vs. placebo). Primary objective is median PFS. Data is expected around Q3 2025.
  • Safety: In early 2023, the Phase 2 trial was placed on partial clinical hold by the FDA due to a fatal (grade 5) hepatotoxicity event. The hold was lifted in April 2023 after protocol amendments, including the exclusion of higher-risk elderly patients with a Hepatic Steatosis Index (HSI) score of 36 or higher. An independent Data Safety Monitoring Board (DSMB) recommended trial continuation in April 2024.
• Ewing Sarcoma:
  • Phase 1 Data (Interim, as of September 8, 2023): In a cohort evaluating ozekibart (INBRX-109) in combination with Irinotecan and Temozolomide, 13 evaluable patients showed a disease control rate of 76.9% (10 out of 13 patients), with 53.8% achieving PRs and 23.1% achieving SD. The combination was well-tolerated. Recruitment for this cohort has been expanded by 50 patients, with interim data expected in H2 2025.
• Colorectal Adenocarcinoma (CRC):
  • Phase 1 Data (Interim, as of December 2, 2024): In a cohort evaluating ozekibart (INBRX-109) in combination with FOLFIRI, 10 of 13 evaluable patients demonstrated an objective response rate (ORR) of 30.8% (1 complete response, 3 partial responses) and a DCR of 76.9% (6 stable disease cases). Durable disease control (≥180 days) was observed in 46.2% of patients, with a median PFS of 7.85 months. Recruitment for this cohort has been expanded by 50 patients (with 2-3 prior lines of systemic therapy), with data anticipated in Q3 2025.

Market Dynamics: Chondrosarcoma, Ewing sarcoma, and colorectal cancer are aggressive diseases, with chondrosarcoma and Ewing sarcoma being orphan oncology indications. These conditions often respond poorly to currently approved therapies, representing a significant unmet medical need.

INBRX-106

Financial Performance: Research and development expenses are tracked in aggregate and not allocated by specific program.

Product Portfolio: INBRX-106 is a precisely engineered hexavalent sdAb-based therapeutic candidate targeting OX40, designed as an optimized agonist of this co-stimulatory receptor to enhance anti-tumor immunity. It is composed of six OX40 targeting sdAbs and a functional Fc domain.

Key Growth Drivers:

• Phase 1/2 Clinical Trial: Initiated in December 2019 for patients with locally advanced or metastatic solid tumors.
  • Part 1 (Single Agent Dose Escalation): Generally well-tolerated in 20 patients, with most adverse events (AEs) being Grade 1 and 2 cutaneous toxicities. Maximum tolerated dose (MTD) was not reached at 3 mg/kg.
  • Part 3 (Combination with KEYTRUDA®): Completed dose escalation in combination with KEYTRUDA® (pembrolizumab), a PD-1 blocking checkpoint inhibitor. Observed to be well-tolerated with predominantly mild or moderate non-serious immune-related toxicities and durable responses across multiple tumor types.
  • Part 4 (Combination Expansion Cohorts, as of January 3, 2025):
    • Non-Small Cell Lung Cancer (NSCLC): In 24 patients with previous checkpoint inhibitor exposure, tumor reduction or stabilization of target lesions was observed in more than half, including one complete response (CR) and four partial responses (PRs). This cohort has been expanded.
    • Head and Neck Squamous Cell Carcinoma (HNSCC): In 14 patients (seven checkpoint failures, seven checkpoint naive), tumor reduction of target lesions was observed in half, including two CRs and five PRs. This cohort has been expanded.
    • A new cohort in NSCLC patients (any PD-L1 status) has been added to evaluate the safety of chemotherapy in conjunction with INBRX-106 and KEYTRUDA®.
    • A more mature dataset for these cohorts is expected in Q4 2025.
• Seamless Phase 2/3 Clinical Trial: Initiated in June 2024 for INBRX-106 in combination with KEYTRUDA® as a first-line treatment for patients with locally advanced recurrent or metastatic HNSCC (PDL-1 combined positive score (CPS) ≥ 20, checkpoint inhibitor naive).
  • Phase 2 Portion: Plans to enroll approximately 60 patients with a primary endpoint of ORR. Initial data is expected in Q4 2025.
  • Phase 3 Portion: Pending positive Phase 2 data, will enroll approximately 350 patients randomized to INBRX-106 or placebo in combination with KEYTRUDA®. Co-primary endpoints will be PFS and overall survival.

Market Dynamics: Despite the success of checkpoint inhibitor immunotherapies, a majority of patients do not respond. INBRX-106 aims to provide co-stimulation to T-cells, potentially enhancing anti-tumor immunity and addressing this unmet medical need.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Not disclosed.
• Dividend Payments: Inhibrx Biosciences, Inc. has never declared or paid cash dividends and intends to retain all available funds and future earnings for business operations and expansion.
• Dividend Yield: N/A
• Future Capital Return Commitments: No specific commitments for future capital returns are disclosed.

Balance Sheet Position:

• Cash and Equivalents: $152.6 million as of December 31, 2024, down from $277.9 million as of December 31, 2023.
• Total Debt: $0 as of December 31, 2024, significantly down from $207.0 million as of December 31, 2023. This reduction is due to the Acquirer assuming the company's outstanding debt in connection with the May 2024 Merger.
• Net Cash Position: $152.6 million as of December 31, 2024.
• Credit Rating: Not disclosed.
• Debt Maturity Profile: In January 2025, Inhibrx Biosciences, Inc. entered into a new Loan and Security Agreement with Oxford Finance LLC for a Term Loan Facility of up to $150.0 million. An initial $100.0 million was funded, with an option for an additional $50.0 million at Oxford Finance LLC's discretion. The facility matures on January 1, 2030, with interest-only payments through February 1, 2028, followed by 23 months of principal and interest payments. A final payment of 9.0% of the total repaid principal is due at maturity or prepayment. The obligations are secured by substantially all present and future assets of the company.

Cash Flow Generation:

• Operating Cash Flow: -$194.4 million for the year ended December 31, 2024, compared to -$193.3 million for the year ended December 31, 2023.
• Free Cash Flow: Approximately -$197.0 million for the year ended December 31, 2024 (Operating Cash Flow of -$194.4 million minus Capital Expenditures of $2.6 million).
• Cash Conversion Metrics: Not explicitly disclosed.

Operational Excellence

Production & Service Model: Inhibrx Biosciences, Inc. does not own or operate manufacturing facilities and has no plans to develop its own manufacturing operations in the foreseeable future. It relies on third-party suppliers for raw materials, antibodies, and other biologics for preclinical research and clinical trials. The company also relies on third-party contract development and manufacturing organizations (CDMOs) for clinical supplies and manufacturing scale-up activities. Internal resources are employed to manage these manufacturing relationships. The company has found its therapeutic candidates can be readily manufactured at high yields using established processes.

Supply Chain Architecture: Key Suppliers & Partners:

• Contract Manufacturing Organizations (CDMOs): Provide clinical supplies and support manufacturing scale-up activities for therapeutic candidates.
• Contract Research Organizations (CROs): Conduct preclinical studies and clinical trials.
• Foreign CROs and CMOs: The company utilizes foreign partners, such as WuXi AppTec, which may be subject to U.S. legislation, sanctions, trade restrictions, and foreign regulatory requirements.

Facility Network:

• Headquarters, Laboratory & Office Space: Approximately 43,000 square feet in La Jolla, California, under a lease expiring in 2028 with a three-year extension option. This space is believed to be sufficient for the foreseeable future.
• Manufacturing: Relies entirely on third-party facilities.
• Research & Development: Conducted at its La Jolla, California facilities.

Operational Metrics: Specific operational metrics such as capacity utilization, efficiency measures, or quality indicators are not explicitly disclosed in the filing.

Market Access & Customer Relationships

Go-to-Market Strategy: As Inhibrx Biosciences, Inc. does not currently have any approved products, it has no existing sales, marketing, or distribution capabilities. The company plans to either expand its internal capabilities or enter into collaborations with third parties to commercialize any approved therapeutic candidates in the United States and internationally.

Customer Portfolio: The company's clinical trials are focused on patients with specific oncology indications, including chondrosarcoma, Ewing sarcoma, colorectal cancer, non-small cell lung cancer (NSCLC), and head and neck squamous cell carcinoma (HNSCC). There are no commercial customers at this stage.

Geographic Revenue Distribution: All revenue to date has been derived from license fees and grant awards, not from product sales. The company has not disclosed a geographic breakdown of its license fee revenue.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The biopharmaceutical industry is characterized by rapid technological evolution, intense competition, and robust intellectual property defense.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Novel Therapeutics (sdAb/Alternative Scaffold): Alligator Bioscience AB, Crescendo Biologics Ltd., GlaxoSmithKline plc, Lava Therapeutics N.V., Molecular Partners AG, Precirix NV, Sanofi S.A.
• Antibody Drug Discovery: Regeneron Pharmaceuticals, Inc., Adimab LLC, Genmab A/S, Macrogenics, Inc., Merus N.V., Numab Therapeutics AG, Amgen, Inc., Xencor, Inc., Zymeworks Inc.
• Autoimmune Diseases (general, though company focus is oncology): Sanofi S.A., Amgen Inc., AstraZeneca plc, F. Hoffmann-La Roche AG, Pfizer Inc., Merck & Co., Inc., Novartis AG, Candid Therapeutics, Inc., Hinge Bio, Inc., Apogee Therapeutics, Inc.

Emerging Competitive Threats: The company acknowledges the risk of new entrants, disruptive technologies, and alternative solutions that could render its therapeutic candidates obsolete or less competitive.

Competitive Response Strategy: Inhibrx Biosciences, Inc. aims to leverage its proprietary platforms, technology, knowledge, experience, and scientific resources to maintain competitive advantages.

Risk Assessment Framework

Strategic & Market Risks

• Market Dynamics: The company operates in a highly speculative biotechnology product development environment with a substantial degree of uncertainty and a high historical failure rate for therapeutic candidates. There is no guarantee that clinical trials will be completed on schedule or successfully, and therapeutic candidates may fail at any stage. Market opportunities for current or future therapeutic candidates may be limited to specific patient populations (e.g., orphan diseases) or later-line therapies, potentially smaller than expected.
• Technology Disruption: The company's proprietary modular protein engineering platforms represent a novel and unproven therapeutic approach, which carries inherent risks. Competitors could develop more effective, safer, or less expensive products, or render the company's platforms obsolete through technological advances.
• Customer Concentration: Not applicable as the company has no approved products or commercial customers.

Operational & Execution Risks

• Supply Chain Vulnerabilities: The company relies heavily on third-party contract research organizations (CROs) for clinical trials and contract development and manufacturing organizations (CDMOs) for clinical supplies and manufacturing. This reliance exposes the company to risks of non-performance, failure to meet regulatory requirements, missed deadlines, and difficulties in scaling up manufacturing. The use of foreign CROs and CMOs (e.g., WuXi AppTec) introduces additional risks related to U.S. legislation, sanctions (e.g., BIOSECURE Act), and foreign regulatory requirements.
• Geographic Concentration: Current operations are concentrated in a single location in La Jolla, California, making the company vulnerable to disruptions from natural disasters (e.g., earthquakes, fires, extreme weather) or other unforeseen events.
• Capacity Constraints: Third-party manufacturing partners may be unable to successfully scale up manufacturing of therapeutic candidates in sufficient quality and quantity, which could delay or prevent development and commercialization.

Financial & Regulatory Risks

• Market & Financial Risks: Inhibrx Biosciences, Inc. has a limited operating history and has incurred significant operating losses since inception, with expectations of continued losses. The company will require substantial additional funding, which may not be available on acceptable terms or at all, leading to potential delays or termination of development efforts. Raising capital through equity or debt could result in dilution or restrictive covenants. Inflation could adversely affect liquidity and cost structure. The company's cash and cash equivalents are held at financial institutions, posing a risk in case of bank failures.
• Regulatory & Compliance Risks: The marketing approval processes by the FDA and other regulatory authorities are lengthy, time-consuming, and unpredictable. Therapeutic candidates may not meet safety or efficacy requirements, or may cause undesirable side effects, leading to delays, denial of approval, or restrictive labeling. The company may be required to obtain approval for companion diagnostics, which could cause delays. Post-approval, the company will be subject to ongoing stringent regulations, including those prohibiting off-label promotion. Disruptions at regulatory agencies (e.g., funding shortages, global health concerns) could delay approvals. The company's partnerships in China expose it to stringent Chinese data security and personal information protection laws (e.g., PRC Data Security Law, PIPL) and potential changes in U.S.-China relations. Non-compliance with healthcare laws (e.g., Anti-Kickback Statute, False Claims Act, HIPAA) could result in significant penalties.
• Legal Proceedings: While the company successfully defended a trade secrets case brought by I-Mab Biopharma in 2024, it remains subject to the risk of future litigation, which can be costly and divert management attention.

Geopolitical & External Risks

• Geographic Dependencies: Operations and partnerships in foreign markets, particularly China, expose the company to risks related to local laws, regulations, and geopolitical tensions (e.g., U.S. trade policy, tariffs, UFLPA).
• Trade Relations: Changes in international trade policies and relations could impact supply chains and the ability to operate in certain markets.
• Sanctions & Export Controls: Compliance with U.S. and foreign export/import controls, sanctions, and embargoes (e.g., related to the Russia-Ukraine conflict) could limit activities, impact supply chains, and result in penalties.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• Proprietary Modular Protein Engineering Platforms: Used to develop novel biologic therapeutic candidates.
• Single Domain Antibody (sdAb) Platform: Utilized in the design of therapeutic candidates like ozekibart (INBRX-109) and INBRX-106.
• Multivalent Formats: Optimized for target-centric agonist function, allowing for precise valency.

Innovation Pipeline: The company's strategy is to apply its protein engineering platforms to create differentiated, next-generation therapeutics, with a particular emphasis on oncology. It aims to efficiently identify optimal therapeutic formats customized to target biology.

Intellectual Property Portfolio: As of December 31, 2024:

• Patent Families: 35 solely owned, 2 co-owned with Regeneron Pharmaceuticals, Inc., and 2 co-owned with Phylaxis BioScience, LLC.
• Issued Patents: 23 U.S. patents and 194 foreign patents (including Australia, Canada, China, Europe, Russia, India, Israel, Japan, Mexico, New Zealand, Singapore, South Korea, South Africa).
• Pending Applications: 36 U.S. patent applications, 3 Patent Cooperation Treaty (PCT) applications, and 420 foreign patent applications.
• INBRX-106 Specific: 3 patent families covering composition of matter, methods of use for cancer treatment, and alternative dosing regimens. Expected expiration between 2037 and 2043.
• ozekibart (INBRX-109) Specific: 4 patent families covering composition of matter, methods of use for cancer treatment, formulations, and use in combination with select compounds. Expected expiration between 2036 and 2043.
• sdAb and Multispecific Technologies: 6 patent families covering non-immunogenic single domain antibodies, multispecific molecules, and methods of use. Expected expiration between 2036 and 2041.

Patent Strategy: The company continually assesses and refines its intellectual property strategy, filing additional patent applications as needed. It also relies on trade secrets, data exclusivity, market exclusivity, patent term adjustment, and patent term extensions where available.

Technology Partnerships:

• Regeneron Pharmaceuticals, Inc.: Option and License Agreement (originally with bluebird bio, Inc., then 2seventy bio, Inc.) for exclusive worldwide rights to develop binders and cell therapy products containing sdAbs directed to specified targets. Inhibrx Biosciences, Inc. is entitled to additional fees upon option exercise, developmental milestone payments (up to $51.5 million per therapeutic), and mid-single-digit tiered royalties on future product sales.
• Phylaxis BioScience, LLC: Joint venture and agreements (Contribution Agreement, License Agreement, Limited Liability Company Agreement, Master Services Agreement) for licensing intellectual property and know-how and providing development services. Inhibrx Biosciences, Inc. holds a 15% equity interest and is entitled to specified development and commercialization milestone payments (up to $225.0 million and $175.0 million, respectively) and a percentage of Phylaxis BioScience, LLC's profits.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The company's success is dependent on the continued service of its key management, advisors, and specialized personnel. The current leadership team brings experience from multiple organizations including Genentech, Inc., Gilead Sciences, Inc., Merck & Co., Novartis AG, Pfizer Inc., and Roche.

Board Composition: The board of directors is comprised of individuals with proven business and scientific accomplishments and significant operating knowledge. The audit committee of the board of directors is responsible for the oversight of risks from cybersecurity threats.

Human Capital Strategy

Workforce Composition:

• Total Employees: 161 as of December 31, 2024.
  • 156 are full-time employees.
  • 129 are engaged in research and development activities.
  • 73 employees hold advanced degrees (e.g., Ph.D., M.D., PharmD, J.D., MBA).
• Geographic Distribution: Not explicitly detailed beyond the headquarters in La Jolla, California.
• Skill Mix: The workforce possesses deep scientific, manufacturing, and clinical experience, along with an accomplished commercial team. In-house capabilities span discovery, protein engineering, cell biology, translational research, chemistry, manufacturing and controls (CMC), clinical development, and commercialization.

Talent Management:

• Acquisition & Retention: Compensation programs are designed to attract and retain talent, including competitive base salaries, stock-based compensation awards, bonus plans for all full-time employees, retirement savings options with matching contributions, fully covered healthcare benefits for all full-time employees and their dependents, unlimited vacation, and parental leave. The company also offers internship opportunities.
• Diversity & Development: Committed to fostering talent, the company offers tuition reimbursement for growth and career development, opportunities to attend relevant conferences and symposiums, and in-house coaching. It is an equal opportunity employer.
• Culture & Engagement: The company maintains an innovative culture that encourages scientific risk-taking within a data-driven philosophy.

Employee Wellness, Health, and Safety: The company is committed to employee health and safety, requiring annual workplace safety training and maintaining an Environmental Health and Safety Committee that regularly reviews workplace safety and adherence to policies.

Environmental & Social Impact

Environmental Commitments: Inhibrx Biosciences, Inc. maintains quantities of various flammable and toxic chemicals at its La Jolla, California facilities for research and development. The company states its procedures for storing, handling, and disposing of these hazardous materials comply with relevant federal, state, and local laws and regulations, including those of La Jolla, California, and the Occupational Safety and Health Administration (OSHA).

Supply Chain Sustainability: No specific details regarding supply chain sustainability initiatives or programs are disclosed in the filing.

Social Impact Initiatives: No specific details regarding community investment or product social impact initiatives are disclosed in the filing.

Business Cyclicality & Seasonality

Demand Patterns: As a clinical-stage biopharmaceutical company with no approved products, Inhibrx Biosciences, Inc. does not currently experience business cyclicality or seasonality related to product demand.

Economic Sensitivity: The company's operations and future funding requirements are sensitive to broader financial, economic, and market conditions, including inflation and interest rates.

Industry Cycles: The biopharmaceutical industry is characterized by long development cycles and high capital requirements, which inherently expose the company to industry-specific cyclical patterns related to research, development, and regulatory approval.

Planning & Forecasting: Not explicitly detailed in the filing.

Regulatory Environment & Compliance

Regulatory Framework:

• Industry-Specific Regulations: Inhibrx Biosciences, Inc. is subject to extensive regulation by governmental authorities in the United States (e.g., FDA) and other countries. This includes regulations governing research, development, testing, manufacturing (cGMP), preclinical studies (GLP), clinical trials (GCP), labeling, packaging, promotion, storage, advertising, distribution, marketing, and import/export of therapeutic candidates. The company's therapeutic candidates must undergo the Biologics License Application (BLA) process for marketing approval.
• Expedited Programs: The company has received FDA Fast Track designation and Orphan Drug designation for ozekibart (INBRX-109) for chondrosarcoma. It may seek accelerated approval or other expedited programs for future candidates.
• Post-Approval Requirements: Any approved products will be subject to pervasive and continuing post-marketing regulatory requirements, including record-keeping, adverse event reporting, and restrictions on advertising and promotion.
• Biosimilars and Exclusivity: The Biologics Price Competition and Innovation Act (BPCIA) in the U.S. provides an abbreviated approval pathway for biosimilar products and 12 years of exclusivity for reference biological products, which the company expects its approved therapeutic candidates to qualify for. Similar provisions exist in the EU.
• Companion Diagnostics: If the safe and effective use of a therapeutic product depends on an in vitro diagnostic, the FDA may require contemporaneous approval or clearance of a companion diagnostic, which is regulated as a medical device and typically requires a Premarket Approval (PMA) application for cancer therapies.
• International Compliance: The company is subject to EU and national regulations for clinical trials (EU Clinical Trials Regulation, CTR) and marketing authorization (Centralized or Decentralized procedures). The UK's Medicines and Healthcare products Regulatory Agency (MHRA) now approves medicines for the United Kingdom, with a new international recognition procedure in place since January 2024.

Trade & Export Controls: The company is subject to U.S. and foreign export and import controls, sanctions (e.g., U.S. Export Administration Regulations, OFAC), anti-corruption laws (e.g., U.S. Foreign Corrupt Practices Act), and anti-money laundering laws. The potential passage of the BIOSECURE Act could restrict the company's ability to purchase services or products from certain Chinese biotechnology companies.

Legal Proceedings: In November 2024, the company was successful in a trade secrets case brought by I-Mab Biopharma in the United States District Court for the District of Delaware, with the jury rejecting all allegations of misappropriation. A settlement was reached in January 2025, and the action was dismissed with prejudice.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: Not applicable due to a full valuation allowance against deferred tax assets.
• Geographic Tax Planning: Not explicitly detailed.
• Tax Reform Impact: The company is affected by U.S. healthcare reform legislation, including the Affordable Care Act (ACA) and the Inflation Reduction Act of 2022 (IRA), which impose price negotiations with Medicare, rebates for price increases, and changes to Medicare Part D. The American Rescue Plan Act of 2021 eliminated the statutory cap on manufacturer Medicaid rebates.
• NOL Carryforwards: As of December 31, 2024, the company had unused federal net operating loss (NOL) carryforwards of approximately $20.3 million (indefinite carryforward, 80% taxable income limit) and state NOL carryforwards of approximately $7.8 million (expiring in 2044). The utilization of these NOLs may be subject to annual limitations due to ownership changes under IRC Sections 382 and 383.
• Section 336(e) Election: In connection with the Distribution, the company and the Former Parent made a joint election under Section 336(e) of the Code. This requires Inhibrx Biosciences, Inc. to make annual payments to the Former Parent equal to 85% of its actual cash tax savings realized from the step-up in tax basis of its assets.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: Inhibrx Biosciences, Inc. maintains insurance coverage that it believes is adequate for a business of its size and type, including cyber liability insurance.
• Risk Transfer Mechanisms: Not explicitly detailed beyond general insurance coverage.
• D&O Insurance: The company has not renewed its Directors and Officers (D&O) liability insurance policy due to cost-prohibitive premiums and high retentions. This exposes the company to potential material adverse effects on its financial condition, results of operations, and liquidity if it were to face securities litigation or be required to indemnify its officers and directors.